ERBB2 and colorectal neoplasm: The presence of a BRAF V600E mutation or microsatellite instability may prompt a provider to recommend clinical trials incorporating promising targeted therapies and/or immunotherapy agents, and HER2/neu overexpression or ERBB2 amplification of on colorectal tumors also has significant implications for forthcoming trials with anti-HER2 therapies[5].